Genetics & Risk Factors
Who gets Parkinson's? The answer lies in a complex interaction of rare genes, common variants, environmental exposures, and factors that protect.
Who Gets Parkinson's?
Parkinson's disease affects roughly 1–2% of people over 60, making it the second most common neurodegenerative disease after Alzheimer's. But why does it strike some people and not others? The answer turns out to be deeply complex - and rarely deterministic. Most people with PD have no family history, no clear exposure, and no obvious genetic cause.
Yet genetics, environmental toxins, and lifestyle factors all measurably shift your probability. Understanding those factors is the first step toward prevention - and toward understanding why the disease varies so dramatically from person to person.
The 5–10% vs 90–95% Split
Parkinson's disease is divided into two broad categories based on its cause. Only a minority has a clear single-gene cause.
A single gene mutation is sufficient to cause disease. Includes SNCA, LRRK2 (dominant), and Parkin, PINK1 (recessive). Often presents at younger ages (<50) and is over-represented in research cohorts.
No single gene is causal, but dozens of common genetic variants each nudge risk slightly. GWAS studies have identified 90+ risk loci, with overall heritability estimated at 22–27%. Environment and aging play large roles.
Note: Even within "monogenic" PD, penetrance is incomplete - carrying LRRK2 G2019S gives only a 25–42.5% lifetime risk by age 80. The boundary between monogenic and sporadic is blurrier than it appears.
What this actually means
About 1-2% of people over 60 develop Parkinson's. Only 5-10% of cases are caused by a single gene. The vast majority (90-95%) result from a mix of many small genetic nudges, environmental exposures, and aging. Most people who get Parkinson's have no family history of it.
Picture this: Loaded dice, not destiny. Your genes set the weighting of the dice, the environment decides how many times they get rolled, and aging is the hand that keeps rolling them. A bad roll isn't guaranteed -- but some dice are heavier than others.
Why it matters: Having a relative with Parkinson's raises your risk slightly, but it does not mean you will get it. Even carrying one of the strongest known gene mutations gives only a 25-42% chance of developing the disease by age 80.
Common misconception: Parkinson's is not a 'genetic disease' in the way people usually mean. The vast majority of cases have no clear single-gene cause, and carrying a risk gene does not mean you will develop symptoms.
Who Gets Parkinson's?
Parkinson's disease affects roughly 1–2% of people over 60, making it the second most common neurodegenerative disease after Alzheimer's. But why does it strike some people and not others? The answer turns out to be deeply complex - and rarely deterministic. Most people with PD have no family history, no clear exposure, and no obvious genetic cause.
Yet genetics, environmental toxins, and lifestyle factors all measurably shift your probability. Understanding those factors is the first step toward prevention - and toward understanding why the disease varies so dramatically from person to person.
The 5–10% vs 90–95% Split
Parkinson's disease is divided into two broad categories based on its cause. Only a minority has a clear single-gene cause.
A single gene mutation is sufficient to cause disease. Includes SNCA, LRRK2 (dominant), and Parkin, PINK1 (recessive). Often presents at younger ages (<50) and is over-represented in research cohorts.
No single gene is causal, but dozens of common genetic variants each nudge risk slightly. GWAS studies have identified 90+ risk loci, with overall heritability estimated at 22–27%. Environment and aging play large roles.
Note: Even within "monogenic" PD, penetrance is incomplete - carrying LRRK2 G2019S gives only a 25–42.5% lifetime risk by age 80. The boundary between monogenic and sporadic is blurrier than it appears.
The Major PD Genes
Five genes dominate the landscape of familial and early-onset PD. Each tells a different biological story - from misfolded proteins to failing mitochondria.
LRRK2
Leucine-rich repeat kinase 2
- •Most common dominant PD mutation
- •G2019S variant: up to 40% prevalence in North African Arab and Ashkenazi Jewish populations
- •Penetrance only 25–42.5% by age 80 - carrying the variant does not guarantee disease
- •Kinase activity is increased, making it a drug target
- •LRRK2 inhibitors are in clinical trials
GBA1
Glucocerebrosidase
- •Most common genetic risk factor for PD - found in 5–15% of all patients
- •5 to 30-fold increased risk depending on the variant
- •GBA1 encodes a lysosomal enzyme; loss of function disrupts protein clearance
- •Links PD to Gaucher disease - a lysosomal storage disorder
- •Patients with GBA1 variants tend to have faster cognitive decline
SNCA
Alpha-synuclein
- •First PD gene ever identified - the A53T mutation was discovered in 1997
- •Point mutations (A53T, A30P, E46K) cause rare familial forms
- •Duplications cause moderate PD; triplications cause severe, early-onset disease
- •Dose effect: more alpha-synuclein protein = worse and earlier disease
- •The protein that forms Lewy bodies is encoded by this exact gene
Parkin (PARK2)
E3 ubiquitin ligase
- •Accounts for ~50% of autosomal recessive early-onset PD (onset < 40)
- •Works with PINK1 to tag damaged mitochondria for disposal (mitophagy)
- •Loss of Parkin means damaged mitochondria accumulate and poison neurons
- •Patients often have slower progression and good levodopa response
- •Usually no Lewy bodies - a clue that pathology can vary by gene
PINK1
PTEN-induced kinase 1
- •Second most common cause of autosomal recessive early-onset PD
- •PINK1 is the sensor that detects mitochondrial damage
- •When mitochondrial membrane potential drops, PINK1 accumulates and recruits Parkin
- •Together, PINK1 and Parkin form the primary mitophagy pathway
- •Research target for small molecules that could enhance this protective pathway
What this actually means
Five main genes are linked to Parkinson's. Two (LRRK2, SNCA) need only one bad copy to raise risk. Two (Parkin, PINK1) need two bad copies and tend to cause younger-onset disease. One (GBA1) is the most common risk factor overall. They all point to the same basic problems: cells can't clear out damaged proteins or broken power generators (mitochondria).
Picture this: Each gene is like a different worker in a cellular waste disposal plant. SNCA makes the protein that becomes the garbage. GBA1 runs the recycling centre. Parkin and PINK1 are the team that hauls broken generators to the dump. When any worker fails, waste piles up and the cell chokes.
Why it matters: Understanding which gene is involved helps predict how the disease may progress and which experimental treatments might help. For example, LRRK2 patients are being offered targeted drugs (LRRK2 inhibitors) in clinical trials right now.
Common misconception: Having a Parkinson's gene mutation does not guarantee you will get the disease. Even the strongest known mutation (LRRK2 G2019S) only leads to disease in 25-42% of carriers by age 80.
The Major PD Genes
Five genes dominate the landscape of familial and early-onset PD. Each tells a different biological story - from misfolded proteins to failing mitochondria.
LRRK2
Leucine-rich repeat kinase 2
- •Most common dominant PD mutation
- •G2019S variant: up to 40% prevalence in North African Arab and Ashkenazi Jewish populations
- •Penetrance only 25–42.5% by age 80 - carrying the variant does not guarantee disease
- •Kinase activity is increased, making it a drug target
- •LRRK2 inhibitors are in clinical trials
GBA1
Glucocerebrosidase
- •Most common genetic risk factor for PD - found in 5–15% of all patients
- •5 to 30-fold increased risk depending on the variant
- •GBA1 encodes a lysosomal enzyme; loss of function disrupts protein clearance
- •Links PD to Gaucher disease - a lysosomal storage disorder
- •Patients with GBA1 variants tend to have faster cognitive decline
SNCA
Alpha-synuclein
- •First PD gene ever identified - the A53T mutation was discovered in 1997
- •Point mutations (A53T, A30P, E46K) cause rare familial forms
- •Duplications cause moderate PD; triplications cause severe, early-onset disease
- •Dose effect: more alpha-synuclein protein = worse and earlier disease
- •The protein that forms Lewy bodies is encoded by this exact gene
Parkin (PARK2)
E3 ubiquitin ligase
- •Accounts for ~50% of autosomal recessive early-onset PD (onset < 40)
- •Works with PINK1 to tag damaged mitochondria for disposal (mitophagy)
- •Loss of Parkin means damaged mitochondria accumulate and poison neurons
- •Patients often have slower progression and good levodopa response
- •Usually no Lewy bodies - a clue that pathology can vary by gene
PINK1
PTEN-induced kinase 1
- •Second most common cause of autosomal recessive early-onset PD
- •PINK1 is the sensor that detects mitochondrial damage
- •When mitochondrial membrane potential drops, PINK1 accumulates and recruits Parkin
- •Together, PINK1 and Parkin form the primary mitophagy pathway
- •Research target for small molecules that could enhance this protective pathway
The Polygenic Landscape - GWAS Findings
Beyond the rare, high-impact mutations, large genome-wide association studies (GWAS) have painted a picture of sporadic PD as a polygenic disease - shaped by dozens of common variants, each contributing a small individual effect.
A mega-analysis of 37,688 PD cases and 981,372 controls identified 90+ independent risk loci. Many cluster around genes involved in lysosomal function, vesicle trafficking, and mitochondrial quality control - converging on the same biological pathways implicated by the monogenic genes.
What this actually means
For the 90-95% of cases without a single clear gene, scientists have found over 90 spots in the genome that each slightly raise or lower the risk. Each one has a tiny effect on its own, but together they account for about 22-27% of what determines who gets the disease. Many of these genetic spots affect the same waste-clearing and energy-producing systems as the major genes.
Picture this: If the major genes are like a single heavy weight on one side of a scale, these common variants are like handfuls of sand. No single grain tips the balance, but enough sand can eventually make it lean one way or the other.
Why it matters: This means Parkinson's risk is not all-or-nothing. It is a spectrum. Researchers are working on 'polygenic risk scores' that add up all these small effects to estimate someone's overall risk, which could eventually help with early screening.
The Polygenic Landscape - GWAS Findings
Beyond the rare, high-impact mutations, large genome-wide association studies (GWAS) have painted a picture of sporadic PD as a polygenic disease - shaped by dozens of common variants, each contributing a small individual effect.
A mega-analysis of 37,688 PD cases and 981,372 controls identified 90+ independent risk loci. Many cluster around genes involved in lysosomal function, vesicle trafficking, and mitochondrial quality control - converging on the same biological pathways implicated by the monogenic genes.
Environmental Toxins - The MPTP Story and Beyond
Genetics cannot explain most PD cases. The strongest evidence for environmental causes comes from a tragic accident and decades of epidemiological research linking certain chemicals to dopamine neuron death.
MPTP
In 1982, a group of young adults in California developed sudden, severe Parkinson's syndrome after injecting a synthetic heroin contaminated with MPTP. Neurologist J. William Langston traced it to this industrial chemical. MPTP crosses the blood-brain barrier, is converted to MPP+ by astrocytes, and is selectively taken up by dopamine neurons - where it poisons the mitochondria. This accidental tragedy gave researchers the first reliable animal model of PD.
Rotenone
A natural pesticide derived from tropical plants, rotenone is a complex I inhibitor - it blocks the same mitochondrial enzyme targeted by MPTP. Epidemiological studies show 2–3× increased PD risk in farmers who use it. Like MPTP, rotenone preferentially damages SNc neurons in animal models and produces Lewy body-like inclusions, making it a key tool for studying PD mechanisms.
Paraquat
One of the world's most widely used herbicides, paraquat is structurally similar to MPP+ (the toxic metabolite of MPTP). Studies show 1.5–2.5× increased PD risk with paraquat exposure, with the risk roughly doubling for those who live near fields where it is sprayed. California has banned its use; it remains in widespread global use elsewhere.
Trichloroethylene (TCE)
A solvent once ubiquitous in industrial degreasing, dry cleaning, and even decaffeination, TCE contaminates groundwater at thousands of sites across the US. Studies show 2–6× increased PD risk, including a landmark study of US Marines exposed at Camp Lejeune. The EPA banned most uses of TCE in December 2024. It was used in drinking water at Camp Lejeune for decades.
What this actually means
Certain chemicals can directly damage or kill dopamine neurons. A contaminated street drug (MPTP) proved this dramatically in 1982 when young people developed instant Parkinson's. Pesticides (rotenone, paraquat) and an industrial solvent (TCE) found in groundwater are all linked to significantly increased risk.
Picture this: Dopamine neurons have a vulnerability -- their power generators (mitochondria) can be poisoned by specific chemicals. These toxins are like sugar poured into a gas tank: they don't damage the whole engine, just the fuel system that these particular neurons depend on most.
Why it matters: If you work with pesticides, solvents, or live near industrial sites or agricultural land, this is relevant to your risk. Paraquat remains widely used globally despite its link to Parkinson's. TCE contaminates groundwater at thousands of sites.
Common misconception: These toxins don't cause Parkinson's in everyone who is exposed. They raise risk, especially in people who are also genetically susceptible. Most exposed people will not develop the disease.
Environmental Toxins - The MPTP Story and Beyond
Genetics cannot explain most PD cases. The strongest evidence for environmental causes comes from a tragic accident and decades of epidemiological research linking certain chemicals to dopamine neuron death.
MPTP
In 1982, a group of young adults in California developed sudden, severe Parkinson's syndrome after injecting a synthetic heroin contaminated with MPTP. Neurologist J. William Langston traced it to this industrial chemical. MPTP crosses the blood-brain barrier, is converted to MPP+ by astrocytes, and is selectively taken up by dopamine neurons - where it poisons the mitochondria. This accidental tragedy gave researchers the first reliable animal model of PD.
Rotenone
A natural pesticide derived from tropical plants, rotenone is a complex I inhibitor - it blocks the same mitochondrial enzyme targeted by MPTP. Epidemiological studies show 2–3× increased PD risk in farmers who use it. Like MPTP, rotenone preferentially damages SNc neurons in animal models and produces Lewy body-like inclusions, making it a key tool for studying PD mechanisms.
Paraquat
One of the world's most widely used herbicides, paraquat is structurally similar to MPP+ (the toxic metabolite of MPTP). Studies show 1.5–2.5× increased PD risk with paraquat exposure, with the risk roughly doubling for those who live near fields where it is sprayed. California has banned its use; it remains in widespread global use elsewhere.
Trichloroethylene (TCE)
A solvent once ubiquitous in industrial degreasing, dry cleaning, and even decaffeination, TCE contaminates groundwater at thousands of sites across the US. Studies show 2–6× increased PD risk, including a landmark study of US Marines exposed at Camp Lejeune. The EPA banned most uses of TCE in December 2024. It was used in drinking water at Camp Lejeune for decades.
Protective Factors - What Lowers Risk?
The same epidemiological research that implicates toxins has also uncovered factors that appear to protect against PD. These associations are among the most reproducible in neurology.
Caffeine
Adenosine A2A receptor antagonism appears neuroprotective. Prospective studies show consistent 25–30% reduction in PD risk in regular coffee drinkers - though this is associational, not proven causal.
Exercise
Vigorous aerobic exercise (3+ hours/week) is associated with 20–40% lower PD risk. Exercise increases BDNF, reduces neuroinflammation, and improves mitochondrial function - all mechanistically plausible pathways.
Smoking
Epidemiologically one of the strongest inverse associations in medicine - 40–60% risk reduction. Nicotine may protect dopamine neurons, but the net health cost of smoking far outweighs any neurological benefit. Researchers study nicotinic receptor pathways as drug targets instead.
What this means practically
None of these factors are strong enough to "prevent" PD on their own, especially in someone with high genetic risk. But they suggest that lifelong aerobic exercise is probably the most actionable protective behavior - and one with no harmful side effects.
What this actually means
Three things are consistently linked to lower Parkinson's risk: regular coffee drinking (25-30% lower), vigorous exercise (20-40% lower), and smoking (40-60% lower, but absolutely not recommended due to its other health harms). Of these, exercise is the one you can actually act on safely.
Picture this: Think of brain cells as plants. Exercise is like watering and fertilizing them -- it boosts growth chemicals and reduces inflammation. Caffeine may act as a mild shield. Smoking has a protective effect on these specific cells, but sets fire to everything else in the garden.
Why it matters: Regular vigorous exercise (3+ hours per week) is the single most actionable thing a person can do to lower their Parkinson's risk. It also helps people who already have the disease maintain function longer.
Common misconception: The smoking finding does NOT mean smoking is good for you. The overall health damage from smoking far outweighs any brain protection. Researchers are studying nicotine pathways as drug targets instead.
Protective Factors - What Lowers Risk?
The same epidemiological research that implicates toxins has also uncovered factors that appear to protect against PD. These associations are among the most reproducible in neurology.
Caffeine
Adenosine A2A receptor antagonism appears neuroprotective. Prospective studies show consistent 25–30% reduction in PD risk in regular coffee drinkers - though this is associational, not proven causal.
Exercise
Vigorous aerobic exercise (3+ hours/week) is associated with 20–40% lower PD risk. Exercise increases BDNF, reduces neuroinflammation, and improves mitochondrial function - all mechanistically plausible pathways.
Smoking
Epidemiologically one of the strongest inverse associations in medicine - 40–60% risk reduction. Nicotine may protect dopamine neurons, but the net health cost of smoking far outweighs any neurological benefit. Researchers study nicotinic receptor pathways as drug targets instead.
What this means practically
None of these factors are strong enough to "prevent" PD on their own, especially in someone with high genetic risk. But they suggest that lifelong aerobic exercise is probably the most actionable protective behavior - and one with no harmful side effects.
Gene–Environment Interaction
The most accurate model of PD risk is not genes alone or environment alone - it is their interaction over a lifetime. Imagine a threshold model: each person has a different baseline level of vulnerability, set partly by genetics. Environmental exposures, aging, and lifestyle choices push you toward or away from that threshold.
A farmer carrying GBA1 variants who is heavily exposed to paraquat may cross the threshold decades earlier than either factor alone would predict. Conversely, a LRRK2 G2019S carrier with penetrance of only 25–42.5% who exercises vigorously throughout their life may never develop symptoms at all.
Threshold model - conceptual
Bar widths are illustrative, not from data. They represent relative contribution to PD risk (positive bars) or protection (green bars) based on epidemiological estimates.
What this actually means
Your Parkinson's risk is not set by genes or environment alone -- it is the combination of both, accumulated over a lifetime. Genetics set your starting vulnerability. Chemical exposures, aging, and lifestyle choices push you closer to or further from a tipping point. The same gene mutation can cause disease in one person and nothing in another, depending on what else they are exposed to.
Picture this: Everyone starts at a different height on a hill. Genetic risk factors place you higher up. Toxic exposures are like rain eroding the ground under your feet, pushing you toward the edge. Exercise and other protective factors are like reinforcing the hillside. Whether you go over the edge depends on the total balance.
Why it matters: This is ultimately hopeful: even people with genetic risk factors have some ability to shift their odds through the choices they make, particularly regular exercise. Risk is not fate.
Common misconception: A gene test showing 'increased risk' does not mean the disease is inevitable. Many carriers of even high-risk genes live their entire lives without developing Parkinson's.
Gene–Environment Interaction
The most accurate model of PD risk is not genes alone or environment alone - it is their interaction over a lifetime. Imagine a threshold model: each person has a different baseline level of vulnerability, set partly by genetics. Environmental exposures, aging, and lifestyle choices push you toward or away from that threshold.
A farmer carrying GBA1 variants who is heavily exposed to paraquat may cross the threshold decades earlier than either factor alone would predict. Conversely, a LRRK2 G2019S carrier with penetrance of only 25–42.5% who exercises vigorously throughout their life may never develop symptoms at all.
Threshold model - conceptual
Bar widths are illustrative, not from data. They represent relative contribution to PD risk (positive bars) or protection (green bars) based on epidemiological estimates.
Key Takeaway
What Scientists Know vs. What's Still Uncertain
Established
- LRRK2, GBA1, SNCA, Parkin, and PINK1 are well-established PD genes with clear mechanistic links to disease.
- GWAS has identified 90+ risk loci; heritability of sporadic PD is ~22–27%.
- MPTP directly and reproducibly causes dopamine neuron death in animals and humans.
- Rotenone (2–3x), paraquat (1.5–2.5x), and TCE (2–6x) are consistently associated with elevated PD risk in epidemiological studies.
- Exercise, caffeine consumption, and (as an epidemiological fact) smoking are inversely associated with PD risk.
Still Uncertain
- For most sporadic cases, the specific combination of genetic variants and exposures is not known - we cannot yet predict who will get PD.
- Why LRRK2 G2019S penetrance is only 25–42.5% is poorly understood - what determines whether a carrier develops PD?
- How much of the smoking inverse association is nicotine vs. other compounds vs. a selection bias (PD patients are less likely to smoke due to personality traits)?
- Are the gut microbiome, air pollution, and head trauma genuine PD risk factors, or do confounders explain the associations seen in studies?
- Why do certain populations (North African Arabs, Ashkenazi Jews) carry the LRRK2 G2019S variant at such high frequency?